Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Total Liabilities (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Total Liabilities data on record, last reported at $27.4 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 5.14% year-over-year to $27.4 million; the TTM value through Dec 2025 reached $27.4 million, down 5.14%, while the annual FY2025 figure was $27.4 million, 5.14% down from the prior year.
  • Total Liabilities reached $27.4 million in Q4 2025 per AMLX's latest filing, down from $30.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $124.1 million in Q3 2021 and bottomed at $17.4 million in Q4 2021.
  • Average Total Liabilities over 5 years is $54.2 million, with a median of $49.5 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: soared 191.7% in 2022, then crashed 80.37% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $17.4 million in 2021, then surged by 191.7% to $50.8 million in 2022, then surged by 65.25% to $84.0 million in 2023, then tumbled by 65.64% to $28.9 million in 2024, then dropped by 5.14% to $27.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $27.4 million in Q4 2025, $30.7 million in Q3 2025, and $26.7 million in Q2 2025.